Shanghai Haohai Biological Technology Co (HKSE:06826) Short-Term Debt & Capital Lease Obligation : HK$11 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Shanghai Haohai Biological Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$11 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Shanghai Haohai Biological Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$220 Mil.

Shanghai Haohai Biological Technology Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Short-Term Debt & Capital Lease Obligation Chart

Shanghai Haohai Biological Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

28.61

103.97

80.84

38.39

236.94

Shanghai Haohai Biological Technology Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	56.59	10.73	236.94	10.86

Shanghai Haohai Biological Technology Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Shanghai Haohai Biological Technology Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

688366:China

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Executives

Morgan Stanley	2201 Interest of corporation controlled by you
Dalton Investments Llc	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc	2102 Investment manager
Kabouter Management Llc	2102 Investment manager
Royal Bank Of Canada	2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc	2102 Investment manager
Prudence Investment Management (hong Kong) Limited	2102 Investment manager

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines